Product information and disease descriptionPlace of product in therapyApproaches to treatment
Heterogeneity of treatment effect
13 evidence topics · 10 sources
Summary: heterogeneity evidence for inaxaplin
The sources reviewed report no inaxaplin efficacy results stratified by APOL1 genotype. Of the 64 participants dosed in AMPLITUDE as of the 2024 abstract, 53.1% had the G1/G1, 37.5% the G1/G2, and 9.4% the G2/G2 genotype; efficacy results from that portion have not been published. The differences in response reported to date are by comorbidity and proteinuria level. In AMPLIFIED, the mean change in UACR at week 13 was -42.7% (95% CI -58.3% to -21.1%) in cohort 1 (modest proteinuria, most without diagnosed FSGS) and -17.3% (95% CI -36.3% to 7.2%) in cohort 2 (type 2 diabetes); the confidence intervals were generated post hoc, and the interval for cohort 2 includes no change. In the phase 2a study, the mean UPCR change was -47.7% in the 3 participants with nephrotic-range proteinuria and -47.5% in those with subnephrotic-range proteinuria, and 1 participant with 100% adherence had no reduction. In vitro, inaxaplin inhibited thallium flux in cells expressing G0, G1, and G2 APOL1; a 2026 abstract reports that inaxaplin partially reduced the cytotoxicity of full-length APOL1-G1 and did not rescue toxicity from a nuclear APOL1-G1 fragment produced by cathepsin S. For existing therapies, APOL1 genotype did not modify the effect of blood pressure target or ACE inhibitor treatment on CKD progression in AASK, and did not affect proteinuria response to cyclosporine or mycophenolate mofetil plus dexamethasone in the FSGS Clinical Trial; in AASK, strict blood pressure control was associated with 42% lower mortality in the high-risk genotype group only.
Inaxaplin: response by cohort in AMPLIFIED (modest proteinuria and type 2 diabetes)
Inaxaplin: response by baseline proteinuria range in the phase 2a study
Inaxaplin: APOL1 genotype distribution in the AMPLITUDE phase 2 portion
Inaxaplin: in vitro activity against G0, G1, and G2 APOL1
Inaxaplin: preclinical APOL1-G1 fragments resistant to channel inhibition
Genotype refinement: the p.N264K modifier of APOL1 G2
“The APOL1 p.N264K variant was recently found to genetically and almost completely negate the effect of G2 risk alleles to levels comparable to G0, and this observation has been replicated in subsequent studies, making APOL1 p.N264K the most robust genetic modifier of APOL1 G2 to date.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increase utilization of p.N264K in inclusion criteria of clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Determine the effects of conventional therapies for FSGS and other glomerular diseases in those with APOL1 high-risk genotypes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood pressure target and ACE inhibitor by APOL1 genotype: AASK
“In the AASK study, the primary outcome occurred in 58.1% of the patients in the APOL1 high-risk group and in 36.6% of those in the APOL1 low-risk group (hazard ratio in the high-risk group, 1.88; P<0.001). There was no interaction between APOL1 status and trial interventions or the presence of baseline proteinuria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although baseline proteinuria was a major predictor of disease progression, it did not significantly modify the effect of APOL1 on progression (P = 0.16 for interaction) (Fig. 1B). In addition, there was no significant interaction between APOL1 status and the randomized blood-pressure goal with respect to the progression of chronic kidney disease (P = 0.72 for interaction) (Fig. 1C), nor was there a significant interaction between APOL1 status and the randomized antihypertensive medication with respect to progression (P = 0.72 for interaction)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lack of significant interaction between APOL1 and treatment with an ACE inhibitor suggests that patients in the APOL1 high-risk group still benefit from this class of drugs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality with strict blood pressure control by APOL1 genotype: AASK
“However, a significant interaction was detected between APOL1 risk group and blood pressure control strategy. In the APOL1 high-risk group, risk of death was 42% lower comparing strict versus usual blood pressure control (0.58 [0.35-0.97]). In the APOL1 low-risk group, risk of death comparing strict versus usual blood pressure control was not significantly different (1.09 [0.84-1.43]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Other modifiers of APOL1-associated progression: AASK
“Sociodemographic factors and common risk factors for CKD progression do not seem to alter APOL1–related CKD progression. Additional investigation is needed to identify nontraditional factors that may affect the association between APOL1 and progressive CKD.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunosuppression response by APOL1 genotype: FSGS Clinical Trial
“APOL1 risk genotype did not affect response to either treatment regimen. Individuals with the risk genotype were more likely to progress to ESRD (P<0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The APOL1 risk genotype did not influence proteinuria responses to cyclosporin or mycophenolate mofetil/dexamethasone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote